medicine and life sciences
Scientists in a European collaboration propose a personalized protocol for optimizing stimulation of optic nerve fibers, for the blind, which takes into account feedback from the viewer's brain. The protocol has been tested on artificial neural networks known to simulate the physiology of the entire visual system, from the eye to the visual cortex. The stimulation protocol will be tested in clinical trials with partners in Rome.
Immune cells protect our body against invading pathogens. The chemokine receptor CCR5 on the surface of T cells plays an important role in this process. However, CCR5 also is used by the HI-Virus as entrance gate into T cells. A research consortium led by the University of Basel has now deciphered the mechanism of CCR5 receptor activation. The study provides important insights for the development of effective treatments for AIDS, cancer and inflammatory diseases.
PostDoc position in synthesis and evaluation of novel contrast agents Université de Genève
Professor for Chemistry of Biomaterials and Polymers (80-100%) and Professor for Biointerfaces (80-100%) School of Life Sciences FHNW, Muttenz
Professor*in für Biomaterial- und Polymerchemie und Professor*in für Biointerfaces (beide 80–100 %) Hochschule für Life Sciences FHNW, Muttenz
PhD student in Epidemiology and Biostatistics Universität Bern, Institut für Sozial- und Präventivmedizin
PhD position Soil Exotoxicology Fachhochschule Nordwestschweiz FHNW, Muttenz
Post-doctoral position in statistical genetics Lausanne University Hospital and University of Lausanne
Protection and promotion of native crayfish
How do immune cells get activated?
Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria
New Roche data for Evrysdi
Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia
Novartis announces new interim analysis Phase II data for iptacopan in rare kidney disease C3 glomerulopathy (C3G)
Modelling lungs to limit testing on mice
Approval for New Alzheimer's Drug Developed at UZH
Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN)
Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma
SDGs and USI. End poverty and hunger